Huize (HUIZ) Q4 2025 earnings review
Record Premiums and AI Efficiencies Drive Non-GAAP Profit Surge
Huize delivered a robust second half of 2025, pushing full-year Gross Written Premiums (GWP) to a record RMB 7.43 billion (+20.6% YoY) and Operating Revenue to RMB 1.58 billion (+26.7% YoY). The growth was heavily skewed towards new business, with First Year Premiums (FYP) surging 35.4%, driven by high demand for savings and participating products in a low-interest-rate environment. The company's aggressive deployment of proprietary AI solutions significantly reduced the expense-to-income ratio from 32.2% to 26.3%. While GAAP net profit barely stayed positive at RMB 4.0 million due to a massive H2 spike in share-based compensation, Non-GAAP net profit leaped 169% YoY to RMB 22.6 million.
🐂 Bull Case
The integration of over 700 AI agents and DeepSeek LLMs is visibly flowing to the bottom line. The expense-to-income ratio improved by 5.9 percentage points in FY25, dropping to 26.3%. AI is automating claims, handling 95% of customer inquiries, and boosting self-service policy purchases by 50%.
The company's pivot toward mass-affluent customers (average age 35.3, >65% in Tier 2+ cities) is yielding results. 13th- and 25th-month persistency ratios remain above 95%, ensuring a high-quality recurring revenue foundation.
🐻 Bear Case
Despite a record year, growth was entirely dependent on new sales. FYP skyrocketed 35.4%, but Renewal Premiums grew a mere 2.1%. If new business momentum slows, the overall growth engine will stall.
China's 'Bao Xian Fei' (expense rationalization) regulatory cap on commissions has permanently compressed gross margins into the high 20s. Scaling revenue will require massive volume to yield meaningful absolute profit.
⚖️ Verdict: ⚪
Neutral. Top-line execution is stellar, and management's AI cost-cutting narrative is validated by the data. However, the deceleration in renewal premiums and thin GAAP margins clouded by heavy share-based compensation warrant caution.
Key Themes
Accelerating AI Transformation
Huize has successfully transitioned AI from an internal experiment to a core operational engine. Deploying proprietary AI tools and integrating the DeepSeek large language model into its consumer app has automated core operations like claims processing and customer service. This directly caused the expense-to-income ratio to improve from 32.2% in FY24 to 26.3% in FY25, validating management's claim that AI acts as a scalable foundation with significant operating leverage.
Strategic Shift to Participating & Savings Products
Management anticipated the declining interest rate environment and successfully pivoted the product mix toward customized savings and participating life insurance (e.g., 'Dajia Hui Xuan 2.0'). This captured the massive outflow of capital from low-yield bank deposits, pushing FYP up 35.4% YoY to RMB 4.63 billion.
Southeast Asia International Expansion
While not heavily featured in the latest earnings release, Huize's international arm, Poni Insurtech, remains a vital driver. The acquisition of Global Care in Vietnam and planned expansions into Singapore and the Philippines aim to diversify regulatory risk and reach a target of 30% international revenue contribution by 2026.
Decelerating Renewal Premium Growth
A notable data point contradicts the exceptionally bullish top-line narrative: Renewal Premiums practically stalled, growing only 2.1% YoY to RMB 2.79 billion in FY25 (down from 37.6% of GWP to 33.9% in H2). This indicates the company is relying almost entirely on new customer acquisition and 'rush sales' to drive growth, raising questions about the long-term compounding value of the portfolio.
Share-Based Compensation Dragging GAAP Profit
H2 2025 operating revenue surged 37.5%, yet GAAP Net Profit for the half was a minuscule RMB 1.8 million. The massive gap between GAAP (RMB 1.8M) and Non-GAAP Net Profit (RMB 26.0M) in H2 reveals that share-based compensation spiked significantly to roughly RMB 24.2 million, heavily diluting true shareholder returns.
Macro Impact: Regulatory Margin Compression
China's shift into the '2% era' of unified commission caps continues to restrict profitability. Despite record volume, the business faces a permanently lower margin ceiling. Selling expenses grew 18.9% in H2, outpacing overall FY25 selling expense growth (14.5%), showing that acquiring new premiums is becoming more expensive.
Product Innovation: Million-Yuan Medical Segment
Huize launched 'Xing Xiang Shou 2.0' and 'Chang Xiang An 3.0' to reinforce its competitiveness in the million-yuan medical insurance space. This addresses the long-term structural demand of an aging demographic while diversifying the product catalog away from pure savings.
Other KPIs
Accelerating. Up 37.5% YoY. This strong back-half performance pulled full-year revenue growth up to 26.7%, indicating that demand gained significant momentum as the year progressed.
Up 14.5% YoY. While absolute costs rose due to employee compensation, they grew much slower than operating revenue (+26.7%). This positive operating leverage highlights the successful integration of AI tools replacing manual sales and marketing tasks.
Stable. Up slightly from RMB 233.2 million at the end of 2024. Despite ongoing investments in technology and international M&A, the company is generating enough cash to maintain a healthy balance sheet.
Guidance
Management previously outlined a target for international business (Poni Insurtech, Global Care in Vietnam, Singapore) to account for 30% of total group revenues by 2026. This implies aggressive near-term growth outside Mainland China, though progress updates were notably absent from the FY25 print.
Key Questions
Missing International Breakdown
Management previously guided for international business to reach 30% of total revenue by 2026. Why was the international revenue contribution not explicitly broken out in the FY25 earnings release, and are you still on track for that target?
Renewal Premium Disconnect
First Year Premiums grew 35.4% in 2025, but Renewal Premiums only grew 2.1%. Given your industry-leading 95%+ persistency ratios, why is the renewal growth rate so stagnant, and when do you expect the recent surge in FYP to compound into renewal growth?
Share-Based Compensation Spike
Share-based compensation clearly spiked in H2 2025, creating a RMB 24.2 million gap between GAAP and Non-GAAP net profit. Is this a one-time true-up, or should investors expect SBC to remain at this elevated run-rate moving forward?